Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit

Jonathan Pak, John T. Green, Boris Heifets, Michelle H. Pak, Diana S. Woodruff-Pak

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisition of delay eyeblink classical conditioning in older rabbits, a form of associative learning with striking behavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioning engages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized. Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. Material/Methods: To test further the efficacy of nefiracetam in an animal model that mimics some of the neurobiological and behavioral effects present in AD, we tested 56 older rabbits assigned to 7 treatment groups in the 750 ms delay eyeblink conditioning procedure. Older rabbits were injected with 1.5 mg/kg scopolamine to simulate disruption of the cholinergic system in AD. Three doses of nefiracetam (5, 10, or 15 mg/kg) were also injected in older rabbits receiving 1.5 mg/kg scopolamine. Control groups were treated with 1.5 mg/kg scopolamine + vehicle, vehicle alone, or explicitly unpaired presentations of conditioning stimuli and vehicle or 1.5 mg/kg scopolamine + 15 mg/kg nefiracetam. Results: Rabbits injected with 1.5 mg/kg scopolamine alone were impaired, but a dose of 15 mg/kg nefiracetam reversed significantly the behavioral impairment. Conclusion: Nefiracetam had ameliorating effects on a task impaired in AD in an animal model of AD: older rabbits with cholinergic system antagonism.

Original languageEnglish (US)
JournalMedical Science Monitor
Volume8
Issue number4
StatePublished - 2002
Externally publishedYes

Fingerprint

Scopolamine Hydrobromide
Learning
Alzheimer Disease
Rabbits
Cholinergic Agents
Classical Conditioning
Animal Models
Phase III Clinical Trials
nefiracetam
Cognition
Control Groups
Pharmaceutical Preparations
Conditioning (Psychology)

Keywords

  • Acetylcholine
  • Alzheimer's disease
  • Cognition-enhancing
  • Eyeblink classical conditioning
  • Muscarinic acetylcholine receptors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. / Pak, Jonathan; Green, John T.; Heifets, Boris; Pak, Michelle H.; Woodruff-Pak, Diana S.

In: Medical Science Monitor, Vol. 8, No. 4, 2002.

Research output: Contribution to journalArticle

Pak, Jonathan ; Green, John T. ; Heifets, Boris ; Pak, Michelle H. ; Woodruff-Pak, Diana S. / Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. In: Medical Science Monitor. 2002 ; Vol. 8, No. 4.
@article{f1ac990c09444fe0a8e1f9ebd0fea3ff,
title = "Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit",
abstract = "Background: The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisition of delay eyeblink classical conditioning in older rabbits, a form of associative learning with striking behavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioning engages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized. Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. Material/Methods: To test further the efficacy of nefiracetam in an animal model that mimics some of the neurobiological and behavioral effects present in AD, we tested 56 older rabbits assigned to 7 treatment groups in the 750 ms delay eyeblink conditioning procedure. Older rabbits were injected with 1.5 mg/kg scopolamine to simulate disruption of the cholinergic system in AD. Three doses of nefiracetam (5, 10, or 15 mg/kg) were also injected in older rabbits receiving 1.5 mg/kg scopolamine. Control groups were treated with 1.5 mg/kg scopolamine + vehicle, vehicle alone, or explicitly unpaired presentations of conditioning stimuli and vehicle or 1.5 mg/kg scopolamine + 15 mg/kg nefiracetam. Results: Rabbits injected with 1.5 mg/kg scopolamine alone were impaired, but a dose of 15 mg/kg nefiracetam reversed significantly the behavioral impairment. Conclusion: Nefiracetam had ameliorating effects on a task impaired in AD in an animal model of AD: older rabbits with cholinergic system antagonism.",
keywords = "Acetylcholine, Alzheimer's disease, Cognition-enhancing, Eyeblink classical conditioning, Muscarinic acetylcholine receptors",
author = "Jonathan Pak and Green, {John T.} and Boris Heifets and Pak, {Michelle H.} and Woodruff-Pak, {Diana S.}",
year = "2002",
language = "English (US)",
volume = "8",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "4",

}

TY - JOUR

T1 - Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit

AU - Pak, Jonathan

AU - Green, John T.

AU - Heifets, Boris

AU - Pak, Michelle H.

AU - Woodruff-Pak, Diana S.

PY - 2002

Y1 - 2002

N2 - Background: The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisition of delay eyeblink classical conditioning in older rabbits, a form of associative learning with striking behavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioning engages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized. Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. Material/Methods: To test further the efficacy of nefiracetam in an animal model that mimics some of the neurobiological and behavioral effects present in AD, we tested 56 older rabbits assigned to 7 treatment groups in the 750 ms delay eyeblink conditioning procedure. Older rabbits were injected with 1.5 mg/kg scopolamine to simulate disruption of the cholinergic system in AD. Three doses of nefiracetam (5, 10, or 15 mg/kg) were also injected in older rabbits receiving 1.5 mg/kg scopolamine. Control groups were treated with 1.5 mg/kg scopolamine + vehicle, vehicle alone, or explicitly unpaired presentations of conditioning stimuli and vehicle or 1.5 mg/kg scopolamine + 15 mg/kg nefiracetam. Results: Rabbits injected with 1.5 mg/kg scopolamine alone were impaired, but a dose of 15 mg/kg nefiracetam reversed significantly the behavioral impairment. Conclusion: Nefiracetam had ameliorating effects on a task impaired in AD in an animal model of AD: older rabbits with cholinergic system antagonism.

AB - Background: The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisition of delay eyeblink classical conditioning in older rabbits, a form of associative learning with striking behavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioning engages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized. Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. Material/Methods: To test further the efficacy of nefiracetam in an animal model that mimics some of the neurobiological and behavioral effects present in AD, we tested 56 older rabbits assigned to 7 treatment groups in the 750 ms delay eyeblink conditioning procedure. Older rabbits were injected with 1.5 mg/kg scopolamine to simulate disruption of the cholinergic system in AD. Three doses of nefiracetam (5, 10, or 15 mg/kg) were also injected in older rabbits receiving 1.5 mg/kg scopolamine. Control groups were treated with 1.5 mg/kg scopolamine + vehicle, vehicle alone, or explicitly unpaired presentations of conditioning stimuli and vehicle or 1.5 mg/kg scopolamine + 15 mg/kg nefiracetam. Results: Rabbits injected with 1.5 mg/kg scopolamine alone were impaired, but a dose of 15 mg/kg nefiracetam reversed significantly the behavioral impairment. Conclusion: Nefiracetam had ameliorating effects on a task impaired in AD in an animal model of AD: older rabbits with cholinergic system antagonism.

KW - Acetylcholine

KW - Alzheimer's disease

KW - Cognition-enhancing

KW - Eyeblink classical conditioning

KW - Muscarinic acetylcholine receptors

UR - http://www.scopus.com/inward/record.url?scp=0036239156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036239156&partnerID=8YFLogxK

M3 - Article

C2 - 11951055

AN - SCOPUS:0036239156

VL - 8

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 4

ER -